PLATELET COUNT/SPLEEN DIAMETER RATIO: A NONINVASIVE PARAMETER TO PREDICT THE PRESENCE OF ESOPHAGEAL VARICES

Similar documents
Evaluation and Prognosis of Patients with Cirrhosis

Surveillance for Hepatocellular Carcinoma

Recanalized Umbilical Vein in the Presence of Cirrhosis-Induced Portal Hypertension

CLINICAL CONSEQUENCES OF PORTAL HYPERTENSION

After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH

The State of the Liver in the Adult Patient after Fontan Palliation

Patterns of abnormal LFTs and their differential diagnosis

Optimal Management of Splenic/Portal Vein Thrombosis. David Mauchley University of Colorado

Cirrhosis and HCV. Jonathan Israel M.D.

COMPLICATIONS OF CIRRHOSIS COMPLICATIONS OF CIRRHOSIS OBSERVATIONS OF AN AGING HEPATOLOGIST. Philip C. Delich, M.D.

Recommendations 8/14/2014. Hepatitis C Clinical Approach Primary Care. Purpose of Presentation. HCV Prevalence Year of Birth

DENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis

LIVER CANCER AND TUMOURS

MANAGEMENT OF LIVER CIRRHOSIS

What to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic

Screening for Varices and Prevention of Bleeding

NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum

Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs

Non-invasive evaluation of liver fibrosis: current clinical use and next perspectives (chronic hepatitis C)

Lamivudine for Patients with hronic Hepatitis B and Advanced Liver Disease. From : New England Journal of Medicine

GI Bleeding. Thomas S.Foster,Pharm.D. PHR 961 Integrated Therapeutics

PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT

Appendix G - Identification and Selection of Studies

Epidemiology of Hepatitis C Infection. Pablo Barreiro Service of Infectious Diseases Hospital Carlos III, Madrid

The University of Hong Kong Department of Surgery Division of Esophageal and Upper Gastrointestinal Surgery

Lenox Hill Hospital Department of Surgery General Surgery Goals and Objectives

Transmission of HCV in the United States (CDC estimate)

Francesco Vizzutti. Azienda Ospedaliero Universitaria Careggi, Firenze

The following should be current within the past 6 months:

How you can protect investments, reduce health inequalities and save lives in your borough

What is Barrett s esophagus? How does Barrett s esophagus develop?

CMS Limitations Guide - Laboratory Services

PREVENTION OF HCC BY HEPATITIS C TREATMENT. Morris Sherman University of Toronto

The most serious symptoms of this stage are:

Hepatitis C Infections in Oregon September 2014

AASLD PRACTICE GUIDELINES Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis

The digestive system. Medicine and technology. Normal structure and function Diagnostic methods Example diseases and therapies

Noninvasive Means of Diagnosing Liver Fibrosis in Hepatitis C*

LIVER TUMORS PROFF. S.FLORET

Liver Diseases. An Essential Guide for Nurses and Health Care Professionals

BACKGROUND MEDIA INFORMATION Fast facts about liver disease

By Anne C. Travis, M.D., M.Sc. and John R. Saltzman, M.D., FACG Brigham and Women's Hospital Harvard Medical School Boston, MA

Acute on Chronic Liver Failure: Current Concepts. Disclosures

BURDEN OF LIVER DISEASE IN BRAZIL

UCLA Asian Liver Program

KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA

Study of Effects of Probiotic Lactobacilli in Preventing Major Complications in Patients of Liver Cirrhosis

National Health Burden of CLD in Italy

ECG may be indicated for patients with cardiovascular risk factors

June 11, 2015 Tim Halterman

End Stage Liver Disease: What is New? Marion Peters MD UCSF Berlin 2012

EVALUATION OF LIVER FIBROSIS BY FIBROSCAN

HCV/HIVCo-infection A case study by. Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre

Case Study in the Management of Patients with Hepatocellular Carcinoma

institute, Cairo, Egypt. P.O. BOX: 30 Imbaba, Giza. 3 Tropical Medicine Department, Faculty of Medicine, Ain shams University, Cairo, Egypt.

Alcoholic hepatitis describes liver inflammation caused by drinking alcohol.

GASTROENTEROLOGY FELLOWSHIP HEPATOLOGY ROTATION GOALS AND OBJECTIVES University of Toledo

A 55 year old man with cirrhosis due to chronic hepatitis C (CHC) genotype 3a is referred for liver transplantation.

Preoperative Laboratory and Diagnostic Studies

HEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis

Gastrointestinal bleeding: the management of acute upper gastrointestinal bleeding

EPIDEMIOLOGY OF HEPATITIS B IN IRELAND

Endoscopy and infection: Prevention of infection during endoscopy Treatment of infection by endoscopy. M. Arvanitakis SRBG June 2009

Therapy of decompensated cirrhosis Pre-transplant for HBV and HCV

The pathogenesis of hepatic encephalopathy in

Cirrhosis of liver: Etiological factors, complications and prognosis

LIVER FUNCTION TESTS AND STATINS

a series of fact sheets written by experts in the field of liver disease HCV DISEASE PROGRESSION

Economic Impact of Treatment Options for Hepatic Encephalopathy

PSA Screening for Prostate Cancer Information for Care Providers

HEPATOCELLULAR CARCINOMA (HCC) RESECTION VERSUS TRANSPLANTATION. Francis Yao, M.D.

COMPLICATIONS OF CIRRHOSIS: CASES. Anil Seetharam, MD

PATIENT CONSENT TO PROCEDURE - ROUX-EN-Y GASTRIC BYPASS

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

Early Use of TIPS in Patients with Cirrhosis and Variceal Bleeding

The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery

1 ALPHA-1. The Liver and Alpha-1 Antitrypsin Deficiency (Alpha-1) FOUNDATION FOUNDATION. A patient s guide to Alpha-1 liver disease

Cilostazol versus Clopidogrel after Coronary Stenting

Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness

Clinical Practice Guidelines for Hepatocellular Carcinoma, List of Clinical Questions/Recommendations. Chapter. Grade. CQ No. 1 Interferon Therapy

Hepatitis Panel/Acute Hepatitis Panel

Early Colonoscopy in Patients with Acute Diverticulitis Simon Bar-Meir, M.D.

Prognostic impact of uric acid in patients with stable coronary artery disease

Recommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During

Omega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9

Series 1 Case Studies Adverse Events that Represent Unanticipated Problems: Reporting Required

Examples of good screening tests include: mammography for breast cancer screening and Pap smears for cervical cancer screening.

Liver Failure. Nora Aziz. Bones, Brains & Blood Vessels

Gastrointestinal Bleeding

New Anticoagulants and GI bleeding

LIVER TRANSPLANTATION IN ALAGILLE SYNDROME

CANCER OF THE LIVER HEPATOCELLULAR CARCINOMA

Use of stents in esophageal cancer" Hans Gerdes, M.D. Director, GI Endoscopy Unit Memorial Sloan-Kettering Cancer Center

Hepatocellular Carcinoma: What the hepatologist wants to know

Portal Hypertension and Gastrointestinal Bleeding

The Liver and Alpha-1. Antitrypsin Deficiency (Alpha-1) 1 ALPHA-1 FOUNDATION

Leading the Way to Treat Liver Cancer

HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK

2.1 AST can be measured in heparin plasma or serum. 3 Summary of clinical applications and limitations of measurements

Transcription:

Phil J Gastroenterol 2006; 2: 33-38 PLATELET COUNT/SPLEEN DIAMETER RATIO: A NONINVASIVE PARAMETER TO PREDICT THE PRESENCE OF ESOPHAGEAL VARICES Grace Marie A Legasto, Judy Sevilla, Angelito Balay, Jose A Tan, Lirio V Cham, Arnold Vitug, Armando Sta Ana Section of Gastroenterology, Department of Medicine, Far Eastern University- Nicanor Reyes Medical Foundation (FEU-NRMF) Medical Center, Quezon City, Philippines ABSTRACT Introduction: Variceal bleeding is one of the most dreaded complications of cirrhosis because of its attendant high mortality. The prevalence of varices in patients with cirrhosis is approximately 60-80% and the risk of bleeding is 25-35%. Incidence of first variceal hemorrhage ranges from 20 to 40% within 2 years. Recurrent bleeding occurs in 30% to 40% of patients within the next 2 to 3 days and in up to 60 % within 1 week. Thus, prevention of esophageal variceal bleeding remains at the forefront of long-term management of cirrhotic patients. However, subjecting all patients with cirrhosis to screening endoscopy may not be cost effective. If patients at low or high risk of having esophageal varices (EV) could be identified from easily obtainable clinical variables, a more affordable approach for screening would be possible. The study was conducted to identify clinical, biochemical and ultrasonographic parameters associated with the presence of esophageal varices in patients with compensated cirrhosis. Methodology: This is a cross-sectional study of patients aged 20-84 y/o admitted at the FEU-NRMF Medical Center and the Chinese General Hospital between January 2002 to July 2004 with a diagnosis of cirrhosis based on clinical, biochemical, and/or histopathological data. All patients underwent a complete biochemical work-up, gastroscopy and ultrasonographic measurement of spleen bipolar diameter. Platelet count/spleen diameter ratio was calculated for all patients, tabulated and analyzed. Results: 150 patients underwent blood extractions, ultrasound and upper endoscopy. The prevalence rate of EV was 46%. In the study, the authors found out that age, sex, protime, platelet/spleen diameter ratio, platelet count and spleen diameter were significantly different among patients with or without esophageal varices (NEV), although the platelet count/spleen diameter ratio was the only parameter which was independently associated with the presence of EV in a univariate analysis. A platelet count/spleen diameter ratio cut off value of <160 was highly predictive in the diagnosis EV with a sensitivity of 88.4% (95% CI, 77.9, 94.5) and specificity of 80.2% (95% CI 69.6, 88). Positive and negative predictive values were 79.2% (95% CI 68.2, 87.3) and 89% (95% CI 79, 94.8), respectively.

Platelet Count/Spleen Diameter Ratio 34 INTRODUCTION Chronic liver disease generally progresses slowly from hepatitis to cirrhosis, often over 20 to 40 years. Some forms of liver disease are nonprogressive or only slowly progressive. Other, more severe forms are associated with scarring and architectural disorganization, which, if advanced, lead to cirrhosis. The scarring causes increased resistance to blood flow through the portal vein leading to ascites, esophageal varices, and increased risk of infection. Portal hypertension, a common complication of cirrhosis, results in the development of collaterals to bypass the increased resistance to flow within the portal bed to return blood to the systemic circulation. Gastrointestinal bleeding is the most severe complication of portal hypertension, and esophageal and gastric varices are by far the most common sources of bleeding in these patients. Thirty percent of patients with compensated cirrhosis and 60% of patients with decompensated cirrhosis have gastroesophageal varices at the time of presentation. Mortality is highest in the first 5 days after the index episode of variceal bleeding and returns to baseline levels by 3 to 4 months. This is the critical window for optimal treatment to improve the survival of variceal bleeders. The rate of early rebleeding translates into an increased risk of mortality. It appears that the rate of growth of varices from small to large in compensated cirrhotic patients is faster than the rate of de novo appearance of varices. Therefore, the presence of esophageal varices (EV) is considered a prognostic indicator and a factor affecting the morbidity and mortality of surgical procedures. The American College of Gastroenterology (ACG) recommends endoscopic screening to detect varices in patients with cirrhosis with no previous variceal hemorrhage. If initial endoscopy shows no varices, the examination should be repeated at 2-3 year intervals and at 1-2 year intervals in patients with small varices so as to evaluate its development or progression. In order to reduce the increasing burden of invasive procedures, some studies have attempted to identify noninvasive parameters to predict the presence of esophageal varices. Overall, the most common finding of these studies was that parameters directly linked to portal hypertension such as splenomegaly and decreased platelet count were predictors of the presence of esophageal varices. In patients with chronic liver disease, several factors other than portal hypertension such as myelotoxic effects of alcohol or hepatitis, shortened platelet mean lifespan and decreased thrombopoietin production may decrease platelet count. On the other hand, the presence of splenomegaly in cirrhotic patients is likely the result of vascular disturbance. The study was conducted to determine the association of esophageal varices and platelet count/spleen diameter ratio in patients with compensated cirrhosis. METHODOLOGY This is a cross-sectional study of patients with a diagnosis of cirrhosis based on clinical, biochemical, and/or histopathological data to determine the association of esophageal varices and platelet count/spleen diameter ratio. The study group consisted of patients aged 20-84 years old diagnosed to have cirrhosis who were admitted at the FEU Medical Center or the Chinese General Hospital from January 2002 to July 2004. Patients were asked to sign an informed consent prior to enrollment in the study. Patients were excluded if they had any of the following; 1. hepatocellular carcinoma detected by ultrasonography and/or elevated alpha-feto protein (more than 10 times the upper normal limit of normal) 2. primary hematologic disorders 3. active gastrointestinal bleeding on admission 4. previously known gastrointestinal bleeding 5. taking drugs for primary prophylaxis of variceal bleeding 6. taking alcohol less than 6 months before enrollment 7. history of parenteral drug addiction 8. history of sclerosis or band ligation, trans-

35 Legasto G M, et al. jugular intrahepatic portosystemic stent shunt 9. history of surgery for portal hypertension 10. other diseases with life expectancy of less than one year 11. unstable medical condition At entry, all patients underwent a complete physical examination, laboratory tests which included prothrombin activity, total bilirubin, and platelet count, upper gastrointestinal endoscopy and ultrasonography. Spleen diameter was determined through ultrasonography and was read by one reader. Minimum spleen bipolar diameter was expressed in millimeters (mm). All endoscopy were performed in a single endoscopy center using a video endoscope and esophageal varices were identified by two gastroenterologists who were unaware of the clinical, laboratory and ultrasonographic findings using a consistent single classsification. Platelet count/spleen ratio was calculated for all patients. Definition of Terms 1. Compensated cirrhosis patients without ascites and/or hepatic encephalopathy 2. Splenomegaly diameter of >100mm by ultrasound 3. Normal platelet count: 150-450 x 10 3 /ul 4. Esophageal varices were graded as absent or present and classified using the small and large classification Small: varices in the lower 3 rd of the esophagus and occupied less than a third of the esophageal lumen or minimally protrude into the lumen but did not flatten with air insufflation Large: varices in the lower 3 rd of the esophagus that occupied at least a third of the lumen or protrudes into the esophageal lumen and touch each other ( presence of confluence) and did not flatten with air insufflation RESULTS One hundred-fifty (150) patients were enrolled in the study. One hundred-six (106) patients were men and 44 were women. Using endoscopy, esophageal varices were detected in 69 of the 150 patients examined (46%). The mean age was 51 years among those with esophageal varices and 57 years among those without esophageal varices. Table 1 shows the main variables of the 150 patients included in the univariate comparison of variables between those with and without esophageal varices. Cirrhosis was caused by alcohol ingestion in 135 patients while the cause was hepatitis B in 15 patients. By ultrasonography, 69 were found to have splenomegaly while 81 were found to have normal spleen dimensions. Patients with esophageal varices had significantly lower prothrombin activity and platelet count as compared to those without. Spleen diameter was greater while platelet count/spleen diameter ratio was lower in patients with esophageal varices. Using the platelet count/spleen diameter ratio cut off determined by Giannini et al, a 91.3% prevalence adjusted positive predictive value and a 74% prevalence adjusted negative predictive value for the presence of esophageal varices was obtained. However, using the said cut-off resulted in a 60.9% (95% CI 48.4, 72.2) sensitivity and a 95% (95% CI 87.2, 98.4) specificity. Using the receiver operating characteristic (ROC) curve to assess the platelet count/spleen diameter ratio cut off in this study (Figure 1), a cut-off of 160 was noted to give the best sensitivity and specificity of 88.4% (95% CI 77.9, 94.5) and 80.2% (95% CI 69.6, 88.0), respectively. Using this cut-off, the prevalence adjusted positive and negative predictive values were 79.2% and 89%, respectively. Moreover, accuracy of this platelet/ spleen diameter ratio cut off as evaluated by the kappa coefficient was 0.681 (Table 2). Both spleen diameter and platelet count cut-off with the best sensitivity and specificity for a diagnosis of esophageal varices that were identified by means of ROC curves had prevalence adjusted positive and negative predictive values that were lower than those of the platelet count/spleen diameter ratio. It was determined therefore that a different cut-off of < 160 for the platelet count/spleen diameter was better than the cut-off determined by the previous study when applied to this population.

Platelet Count/Spleen Diameter Ratio 36 TABLE 1. Main characteristics according to the presence of esophageal varices. VARIABLES NEV EV P value Sex (M/F) 49 / 32 57 / 12 0.005 Age (y) 57 51 0.02 Total bilirubin (mg/dl) 6.7 + 11.3 7.4 + 10.8 NS Prothrombin activity 85.3 + 16.7 73.5 + 20.2 <.0001 Platelet count (n/mm3) 202.2 + 84.2 100.33 + 40.7 <.0001 Spleen diameter (mm) 88.6 + 17.4 121.5 + 16.8 <.0001 Platelet count / spleen ratio 240.9 + 119.0 86.3 + 43.1 <.000 NVE: no esophageal varices; EV: esophageal varices Data are + SE: standard of error TABLE 2. Platelet count, spleen diameter and platelet count/spleen diameter ratio of 150 patients according to the presence and absence of esophageal varices VARIABLES NEV EV P value Cut off Kappa coefficient Platelet count (n/mm3) 202.235 100.333 <.0001 < 115 0.63 Spleen diameter (mm) 88.62 121.46 <.0001 > 88 0.507 Plt ct /spleen ratio 240.87 86.267 <.0001 < 160 0.681 NVE: no esophageal varices; EV: esophageal varices Parameter cut off were identified by means of ROC curves SENSITIVITY 95 90 85 80 75 Spleen Diameter 0 10 20 30 40 1-SPECIFICITY FIGURE 1A Receiver operating characteristic curve using spleen diameter

37 Legasto G M, et al. FIGURE 1B Receiver operating characteristic curve using platelet count Platelet Count SENSITIVITY 100 80 60 40 20 0 0 20 40 60 1-SPECIFICITY FIGURE 1C Receiver operating characteristic curve using platelet count/spleen diameter ratio Platelet Count / Spleen Diameter Ratio SENSITIVITY 150 100 50 0 0 10 20 30 40 1-SPECIFICITY DISCUSSION Due to the increasing prevalence of chronic liver diseases, variceal hemorrhage is associated with significant morbidity, mortality, and health care costs. Numerous studies have demonstrated the efficacy of pharmacotherapy for primary prevention of variceal bleeding in patients with high-risk varices indicating the importance of screening for the presence of esophageal varices. Therefore, there is a particular need for noninvasive predictor for the presence of esophageal varices as that might ease the medical, social and economic burden of the disease. Based on the present study it was found that a simple non-invasive technique may be used as a reliable predictor for the presence of esophageal varices among cirrhotic patients. The platelet count/spleen diameter ratio was deemed to be the appropriate parameter to be used as splenomegaly is implicated in thrombocytopenia of cirrhosis with spleen size being inversely correlated with platelet count. The use of this ratio normalizes platelet count to splenic sequestration since platelet count alone maybe misleading and cannot be solely attributed to portal hypertension. Likewise, the measurement of the spleen bipolar diameter using ultrasonography is easily obtainable, reproducible and non-invasive and is routinely performed on patients with cirrhosis. The focus was on the presence of any esophageal varices whether it be small or large as this is the first step in the diagnostic/prognostic work-up of

Platelet Count/Spleen Diameter Ratio 38 cirrhotic patients which later will prove important in the decision-making process. Moreover, analysis of the presence and absence of esophageal varices prevents misinterpretation of data and allows generalization of the results. Although this study had a small sample population, based on the inferred results, the use of platelet count /spleen diameter ratio showed a good result in discriminating absence or presence of esophageal varices. From the statistical standpoint, it is the only independent parameter associated with the presence of esophageal varices. It should be noted that even among patients with compensated cirrhosis, platelet count/spleen diameter ratio were significantly different between those with and without esophageal varices. The use of platelet count/ spleen diameter ratio would have avoided unnecessary endoscopy in all patients without running a significant risk of missing the presence of esophageal varices. The use of this strategy of using non-invasive tests would necessarily lower the cost of management of cirrhotic patients since no additional expense would be entailed with the use of ultrasonography as cirrhotic patients usually undergo annual/biannual abdominal ultrasonography as part of the surveillance program for hepatocellular carcinoma. As the yearly incidence of esophageal varices in patients with cirrhosis is approximately 5%, it is felt that the use of these non-invasive diagnostic modality would provide an affordable alternative to to detection of esophageal varices among cirrhotic patients. esophageal varices in patient with liver cirrhosis. J Hepatol 1999;14:867-73. 5. Ng Ph, Wong Sy, et al Prediction in esophageal varices in patient with liver cirrhosis. J Gastro Hepatol 1999;14:785-90. 6. Schepia Cammura et al, which patient undergo endoscopic screening for esophageal varices detection hepatol 2001;33:333-8. 7. Garcia tsao et al Predicting the presence of significant portal hypertension and varices in cirrhotic patient, Hepatol 1997;26:360. 8. De Bac et al Liver cirrhosis epidemiological aspects, res viral 1997;148:139-42. 9. Rigoe G angeloni et al, Endoscopic screening in patients with liver cirrhosis; Hepatol 2002;35:501-2 10. Freeman JG, Darlow S., et al Platelet count as a predictor for esophageal varices in patients who are alcoholic, Gastroenterology 1999, 116-117 E. Giannini et al. Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of esophageal varices in patients with liver cirrhosis, Gut 2003, 52:1200-1205. REFERENCES 1. De Franchis R et al. Natural history of portal hypertension in patients with cirrhosis. Clin Liver disease 2001;5:645-63. 2. Graham D. Smith JL. The course of patient after variceal bleeding. Gastroenterology 1981;80;800-9. 3. D Amico G. Garcia-Tsao G., Cales P. et al diagnosis of portal hypertension How and When. Third Baveno International Consensus Workshop on Definitions Methodology and Therapeutic Strategies: Oxford Blackwell science 2001;36-63. 4. Pilette C. Oberji et al, Non invasive diagnosis of